Literature DB >> 25403088

Primary diffuse large B-cell lymphoma of the ovary is of a germinal centre B-cell-like phenotype.

Jian Sun1, Jing Zhang, Qing Ling, Yufeng Luo, Shafei Wu, Zhiyong Liang, Dingrong Zhong, Xuan Zeng.   

Abstract

Primary ovarian lymphoma is rare. To better understand the clinicopathological and molecular features of these tumours, we studied 14 patients (age range 13 to 74 years, mean 46.9 years) with non-Hodgkin's lymphoma who initially presented with an ovarian tumour. The clinicopathological features were reviewed and tissue samples were studied by immunohistochemistry and for immunoglobulin gene rearrangement, presence of Epstein Barr virus and for MYC and BCL-2 rearrangements by fluorescence in situ hybridisation. The most common symptoms were abdominal pain and abdominal distension. Ten patients had a unilateral (7 left, 3 right) ovarian mass and 4 had bilateral ovarian masses, size range 4 to 13 cm (mean, 7.9 cm). Of the 14 lymphomas, 12 were classified as diffuse large B-cell lymphoma (DLBCL) and 2 as Burkitt lymphoma. The Burkitt lymphomas had a MYC rearrangement. The DLBCLs were of the germinal centre B-cell-like subtype. One DLBCL patient had MYC and BCL2 rearrangements. The treatment consisted of various combinations of surgery, chemotherapy and radiotherapy. The follow-up period ranged from 3 to 56 months. During the follow-up period, 8 patients died of disease, 4 were alive with disease, and 2 were alive without disease. Most primary ovarian lymphomas are of germinal centre B-cell-like subtype DLBCL, which have high proliferative activity and poor prognosis.

Entities:  

Mesh:

Year:  2014        PMID: 25403088     DOI: 10.1007/s00428-014-1682-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  25 in total

Review 1.  Non-Hodgkin's lymphoma involving the gynecologic tract: a review of 88 cases.

Authors:  R Vang; L J Medeiros; G N Fuller; A H Sarris; M Deavers
Journal:  Adv Anat Pathol       Date:  2001-07       Impact factor: 3.875

2.  Clinical features and treatment outcomes of 14 cases of primary ovarian non-Hodgkin's lymphoma: a single-center experience.

Authors:  Xiao-Ying Zhao; Xiao-Nan Hong; Jun-Ning Cao; Shiang-Jiin Leaw; Ye Guo; Zi-Ting Li; Jian-Hua Chang
Journal:  Med Oncol       Date:  2010-05-28       Impact factor: 3.064

Review 3.  MYC/BCL2 double-hit high-grade B-cell lymphoma.

Authors:  Shaoying Li; Pei Lin; Ken H Young; Rashmi Kanagal-Shamanna; C Cameron Yin; L Jeffrey Medeiros
Journal:  Adv Anat Pathol       Date:  2013-09       Impact factor: 3.875

4.  Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.

Authors:  Xin-xin Cao; Jian Li; Wei Zhang; Ming-hui Duan; Ti Shen; Dao-bin Zhou
Journal:  Ann Hematol       Date:  2014-01-10       Impact factor: 3.673

5.  [Clinical staging classification of non-Hodgkin's lymphomas (author's transl)].

Authors:  K Musshoff
Journal:  Strahlentherapie       Date:  1977-04

Review 6.  Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy.

Authors:  M A Dimopoulos; D Daliani; W Pugh; D Gershenson; F Cabanillas; A H Sarris
Journal:  Gynecol Oncol       Date:  1997-03       Impact factor: 5.482

7.  Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma.

Authors:  Jian Sun; Zhaohui Lu; Di Yang; Jie Chen
Journal:  Mod Pathol       Date:  2011-03-18       Impact factor: 7.842

8.  Primary malignant lymphoma of the ovary: an unusual presentation of a rare disease.

Authors:  H Mansouri; H Sifat; M Gaye; K Hassouni; A Mansouri; B El Gueddari
Journal:  Eur J Gynaecol Oncol       Date:  2000       Impact factor: 0.196

Review 9.  Ovarian non-Hodgkin's lymphoma: a clinicopathologic study of eight primary cases.

Authors:  R Vang; L J Medeiros; R A Warnke; J P Higgins; M T Deavers
Journal:  Mod Pathol       Date:  2001-11       Impact factor: 7.842

10.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

View more
  5 in total

Review 1.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014-December 2014.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-03-07       Impact factor: 0.196

Review 2.  Early ovariectomy reveals the germline encoding of natural anti-A- and Tn-cross-reactive immunoglobulin M (IgM) arising from developmental O-GalNAc glycosylations. (Germline-encoded natural anti-A/Tn cross-reactive IgM).

Authors:  Peter Arend
Journal:  Cancer Med       Date:  2017-06-05       Impact factor: 4.452

Review 3.  Primary ovarian Burkitt's lymphoma: a rare oncological problem in gynaecology: a review of literature.

Authors:  Anna Stepniak; Piotr Czuczwar; Piotr Szkodziak; Ewa Wozniakowska; Slawomir Wozniak; Tomasz Paszkowski
Journal:  Arch Gynecol Obstet       Date:  2017-08-02       Impact factor: 2.344

Review 4.  Double-Hit Lymphoma (MYC and BCL6) with Involvement of Skull and Adnexal Lesions: A Case Report and a Review of the Literature.

Authors:  Hamza Minhas; Cherif Abdelmalek; Marium Khan; James E O'Donnell; Vladimir Gotlieb; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2018-08-30

5.  Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status.

Authors:  Xinyu Ren; Yin Cheng; Shafei Wu; Xuan Zeng; Xiaohua Shi; Qing Ling; Zongzhu Li; Zhiyong Liang; Beverly Wang
Journal:  Diagn Pathol       Date:  2020-04-01       Impact factor: 3.196

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.